Signant Health’s Clinical Scientist Jennifer Olt Receives ISCTM New Investigator Award May 11, 2022 Signant Health Posted in Scientific Advisory Share: LinkedInTweet Jennifer Olt, Ph.D., a Clinical Scientist from Signant Health’s Operations – Clinical Science team, accepted a 2022 New Investigator Award at the International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) 18th Annual Scientific Meeting in February 2022. The ISCTM New Investigator (NI) program welcomes new talent into the society and advances up-and-coming leaders in clinical trial design and other methodological issues that confound central nervous system (CNS) drug development. Chosen from an impressive applicant pool, Jennifer is one of four NI Award recipients and will hold her appointment for one year. She was also provided two mentors, one from academia and another from the pharmaceutical industry, for the duration of the conference. Jennifer’s award-winning research project provided insights into how quality of life as reported by people with schizophrenia compares with clinician measurements. She co-authored the research with her Clinical Science team colleagues at Signant. Her research concluded there is a poor correlation between patient and clinician scale measurements in severely impaired patients. Since measurement scales are used by regulatory bodies to determine drug efficacy, safety, and patients’ quality of life, Jennifer’s research shows the potential need to ask different questions entirely to determine their accurate measurement for schizophrenia. “Being able to share these research findings with leading experts in the area of Schizophrenia was an exciting opportunity to showcase Signant’s expertise in schizophrenia studies,” Jennifer said. “It also demonstrates our scientific curiosity and excellence in patient-reported outcomes.” For more on Signant’s work related to schizophrenia clinical trials and solutions, download our brochure or visit the link here. Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Recent Posts Data Analytics Clinical Trial Data: Navigating Audit Trail Data Regulations and Accessibility Challenges Apr 18, 2024 James Stringer Learn more eCOA Webinar Recap: Unleashing the Power of PROs Throughout Oncology Drug Development Feb 28, 2024 Signant Health Learn more eCOA 7 eCOA Solution Design Recommendations: Applied Insights from Trial Sites and CRAs Feb 12, 2024 Katie Garner Learn more General 5 Top Clinical Research Themes and Trends of 2023 (and 2024) Jan 02, 2024 Signant Health Learn more eCOA Webinar Recap: How EDC Can Support Modern Clinical Trials Dec 08, 2023 Signant Health Learn more
Jennifer Olt, Ph.D., a Clinical Scientist from Signant Health’s Operations – Clinical Science team, accepted a 2022 New Investigator Award at the International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) 18th Annual Scientific Meeting in February 2022. The ISCTM New Investigator (NI) program welcomes new talent into the society and advances up-and-coming leaders in clinical trial design and other methodological issues that confound central nervous system (CNS) drug development. Chosen from an impressive applicant pool, Jennifer is one of four NI Award recipients and will hold her appointment for one year. She was also provided two mentors, one from academia and another from the pharmaceutical industry, for the duration of the conference. Jennifer’s award-winning research project provided insights into how quality of life as reported by people with schizophrenia compares with clinician measurements. She co-authored the research with her Clinical Science team colleagues at Signant. Her research concluded there is a poor correlation between patient and clinician scale measurements in severely impaired patients. Since measurement scales are used by regulatory bodies to determine drug efficacy, safety, and patients’ quality of life, Jennifer’s research shows the potential need to ask different questions entirely to determine their accurate measurement for schizophrenia. “Being able to share these research findings with leading experts in the area of Schizophrenia was an exciting opportunity to showcase Signant’s expertise in schizophrenia studies,” Jennifer said. “It also demonstrates our scientific curiosity and excellence in patient-reported outcomes.” For more on Signant’s work related to schizophrenia clinical trials and solutions, download our brochure or visit the link here. Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.